MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ijd.17038

Медицинская библиотека · International journal of dermatology · 2024

Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.

Mastorino Luca, Dapavo Paolo, Burzi Lorenza, Rosset Francois, Giunipero di Corteranzo Isotta, Leo Francesco, Verrone Anna, Stroppiana Elena, Ortoncelli Michela, Ribero Simone, Quaglino Pietro

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Brodalumab is a monoclonal antibody and IL-17 RA inhibitor that is approved for the treatment of moderate-to-severe psoriasis. The present study aims to estimate the drug survival (DS), effectiveness, and safety of brodalumab over a period of 156 weeks.

METHODS

The primary objectives were: (i) to determine the treatment response rate at Weeks 16, 28, 52, 78, 104, and 156 as defined by PASI100, PASI90, and an absolute PASI ≤ 3 and (ii) long-term DS. Secondary objectives included the evaluation of possible predictive factors associated with the achievement of response outcomes, and possible predictive factors associated with lower DS.

RESULTS

The treatment response was rapid, with 80.3% of patients achieving PASI ≤ 3, 66% PASI90, and 54.3% the complete clearance of disease at Week 16. The response improved at Week 28, when a plateau was achieved with mild loss of response at later time points, in particular for PASI100 and PASI90 in 55.2 and 65.5% of patients, respectively, at Week 156. After 156 weeks of treatment, 66.22% of patients were still on therapy, and the previous use of IL-17 inhibitors appeared to be associated with an increased risk of treatment discontinuation (HR: 2.51, CI: 1.06-5.98, P = 0.037), and achievement of PASI ≤ 3 until Week 16 with less risk (HR: 0.27 CI: 0.14-0.51, P < 0.001). Bio-naïve status was favorably associated with treatment response, while high BMI negatively affected the achievement of outcomes.

CONCLUSION

Our study confirms the good effectiveness and favorable safety profile of brodalumab in a real-world setting for up to 3 years of treatment.

Для цитирования: Mastorino Luca, Dapavo Paolo, Burzi Lorenza, Rosset Francois, Giunipero di Corteranzo Isotta, Leo Francesco, Verrone Anna, Stroppiana Elena, Ortoncelli Michela, Ribero Simone, Quaglino Pietro. Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3 years.. International journal of dermatology. 2024. DOI: 10.1111/ijd.17038.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.